# Labcorp Inc. | LH | NYSE  

**Analyst Rating:** BUY – Well‐positioned to benefit from sustained diagnostic demand and margin expansion.  
**Target Price (USD, 12‐mo):** $260 – implies ~16× FY2026E EPS (modest premium vs historical ~15× and peers).  
**Report Date:** 2025-05-13  
**Last Close:** ~$240 (2025-05-13) ▪ **52-Week Range:** ~$206–266 ▪ **Market Cap:** ~$21B ▪ **Dividend (ttm):** $2.88 ($0.72/qtr) ▪ **Shares O/S:** ~84M  

**Valuation (Consensus):** FY2025 P/E ~15.5×; FY2024 P/E ~16.4×; P/S ~1.5; P/B ~2.5.  
**Sector:** Healthcare – Diagnostics/Services ▪ **Sector Stance:** MARKET-WEIGHT  
**Financial Str:** Medium-High (strong cash flows; moderate leverage)  

## Analyst’s Notes  
• **Q1 Results:** Revenue $3.35B (+5.3% YoY) and Adj. EPS $3.84 exceeded estimates ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=non,84)). Diagnostic lab sales grew ~6% in Q1 to $2.63B ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=non,35%20billion%2C%20slightly%20below%20the)) as patients (especially older adults) caught up on postponed procedures ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=Labcorp%20surpassed%20analysts%27%20profit%20expectations,35%20billion%2C%20slightly%20below%20the)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-estimates-diagnostic-test-demand-2024-10-24/#:~:text=revenue%20due%20to%20high%20demand,50%20per%20share)). Biopharma services earned $721M (+1–2% driven by R&D testing) with stable margins (14.8% vs 14.1% a year ago) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Total%20Revenue%20%20,4%29%7D)).  
• **Guidance:** Company reaffirmed FY 2025 revenue +6.7–8.0% and free cash ~flat, and raised the EPS midpoint by $0.05 to **$15.70–16.40** ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=,25%20billion)). Consensus was ~$15.8 mid. Updated guide reflects continued volume growth and pricing gains, partly offset by acquisition integration costs.  
• **Growth Drivers:** Management cites demographic tailwinds and expanded testing (oncology, neuro, women’s health) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=strengthened%20their%20positions%20by%20managing,Reflecting%20confidence%20in)). New test launches (e.g. Labcorp Plasma Complete liquid biopsy, Alzheimer’s pTau-217) and acquisitions (e.g. Invitae’s genomic tests) are expected to add future revenue ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=,the%20diagnosis%20of%20Alzheimer%27s%20disease)) ([www.reuters.com](https://www.reuters.com/markets/deals/clinical-lab-operator-labcorp-buy-bankrupt-genetic-test-maker-invitae-239-mln-2024-04-25/#:~:text=Labcorp%2C%20a%20laboratory%20service%20provider%2C,basis%2C%20ensuring%20continuity%20of%20operations)). We expect high-single-digit core volume growth in 2025 and improving mix toward high-value testing.  
• **Margins & Cash:** Q1 operating leverage was strong: diagnostic AOI grew more than sales, with margins moderating only 60bp on one fewer day and weather effects ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Earnings%20Summary%C2%A0,restructuring%20charges%2C%20special%20items%2C%20and)). Full-year 2024 FCF was $1.10B ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Diagnostics%20Laboratories%C2%A0,%241.25)) (~8.5% of sales), supporting $750M in buybacks/dividends ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt)). Net debt ~0.8× equity (cash $1.5B vs debt $6.33B ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt))), ensuring financial flexibility.  
• **Strategic Position:** Labcorp leads with an integrated diagnostics and drug-development platform ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)). We see room for multiple expansion as earnings accelerate and market awareness grows. Key catalysts: execution of new-test rollouts and further accretive acquisitions (MedTech/analytics).  

## Investment Thesis  
Labcorp is well‐placed in a secularly growing healthcare niche. The U.S. clinical laboratory market (~$100B) benefits from aging populations, increased wellness initiatives and rising R&D spending. Labcorp’s diagnostics labs perform ~700 million tests/year globally ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)). Post-pandemic, elective procedure catch-up among older patients continues to drive strong volumes ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=Labcorp%20surpassed%20analysts%27%20profit%20expectations,35%20billion%2C%20slightly%20below%20the)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-estimates-diagnostic-test-demand-2024-10-24/#:~:text=revenue%20due%20to%20high%20demand,50%20per%20share)). Meanwhile, its Biopharma (drug development) segment supports ~75% of new FDA-approved therapeutics ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)) – a diversified revenue stream tied to pharma and biotech R&D. Together, these pillars give Labcorp a broad addressable market spanning preventive healthcare and clinical trials.  

The company offers steady free-cash‐flow generation and modest dividend yields (~1.2%) with growth. Adj. EBIT margins (~20% in diagnostics, mid-teens overall) are high for service industries, enabling robust FCF ($1.1B in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,2))). That cash finances a $0.72/qtr dividend and share repurchases (~$250M in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt))), while allowing selective bolt-on M&A to drive future growth (e.g. Invitae genetics) ([www.reuters.com](https://www.reuters.com/markets/deals/clinical-lab-operator-labcorp-buy-bankrupt-genetic-test-maker-invitae-239-mln-2024-04-25/#:~:text=Labcorp%2C%20a%20laboratory%20service%20provider%2C,basis%2C%20ensuring%20continuity%20of%20operations)). We forecast mid–high-single-digit revenue growth and roughly 10% EPS growth in FY2025, aided by operating leverage. Near‐term catalysts include adoption of new high‐value tests (liquid biopsy, Alzheimer’s panels) and integration of acquisitions, which should help sustain growth beyond the core testing market.  

Geographically, Labcorp’s ~70,000‐emp. network spans ~100 countries ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)), giving it scale economies and resilience to local reimbursement shifts. Longer-term, value‐added services (hospitals partnerships, digital health, data analytics) could further monetize the customer base. In our view, Labcorp’s blend of growth, high margins and cash return capability justifies a **BUY** recommendation. The stock trades below historical P/E levels and key peers; as industry fundamentals and new offerings materialize, we expect an upward re‐rating.  

## Recent Developments  
• **Q1 ’25 Results & Guidance (Apr 29):** Revenue $3.35B (+5.3% YoY), Adj. EPS $3.84 – both topped consensus. Raised FY’25 EPS guide to $15.70–16.40 (midpoint +$0.05) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=,25%20billion)). Confirmed 2025 revenue growth ~7% and FCF ~$1.2B.  
• **Dividend (Apr 10, 2025):** Board declared Q2 dividend $0.72/Q (payable June 11) ([www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorp-declares-quarterly-dividend#:~:text=Inc,business%20on%20May%2029%2C%202025)). Annualized payout $2.88 (coupon ~1.2% at current prices); no cut in last 5 years (steady increase from ~$0.67 in 2021).  
• **Invitae Acquisition (Apr 2024):** Announced acquisition of bankrupt genetic-test maker Invitae’s assets for $239M ([www.reuters.com](https://www.reuters.com/markets/deals/clinical-lab-operator-labcorp-buy-bankrupt-genetic-test-maker-invitae-239-mln-2024-04-25/#:~:text=Labcorp%2C%20a%20laboratory%20service%20provider%2C,basis%2C%20ensuring%20continuity%20of%20operations)). This expands Labcorp’s genomics portfolio (rashly praised), though integration costs trimmed 2024 profit forecasts ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-q2-profit-revenue-estimates-demand-health-tests-2024-08-01/#:~:text=up%20from%20the%20previous%204.8,diagnostics%20unit%2C%20Labcorp%27s%20largest%20revenue)).  
• **Organizational:** Completed spin-off of former Covance clinical trials business into Fortrea (mid-2023); Labcorp now focuses solely on diagnostics & clinical labs. Management (CEO Adam Schechter since 2019) remains stable with consistent strategy execution.  
• **Regulatory/Industry:** No major legal issues. Medicare and insurer payment reforms pose ongoing cost pressures (industry-wide risk). Congress/industry watchers are scrutinizing lab test reimbursement (a bear risk). Recently, a U.S. Supreme Court decision removing class plaintiffs in a billing suit was dismissed (post–5/13, unimpactful).  

## Earnings & Growth Analysis  
Labcorp’s revenues have risen mid‐single digits annually, driven by volume gains, new-to-class tests, and international acquisitions. From FY2022–2024, revenue grew from $11.86B to $13.01B (CAGR ~4.9%) ([www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorp-announces-2023-fourth-quarter-and-full-year-results#:~:text=,66)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,7%20million)). Diagnostics constituted ~$10.1B in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Diagnostics%20Laboratories%C2%A0,%2416.40)), up ~6–7% YoY on volume/mix. Biopharma services (trial labs) grew slower: ~$2.92B in 2024 (+3.0%) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Diagnostics%20Laboratories%C2%A0,%2416.40)), reflecting modest clinical trial activity. We model FY2025 revenue at ~$13.72B (≈7.5% growth) and FY2026 at ~15% above FY2024, assuming continued demand and a full Invitae contribution.

Operating leverage is favorable: most costs are semi-fixed, so incremental revenue flows to the bottom line. In Q1’25, diagnostic AOI rose faster than sales (+6&pct; rev vs +2.3% AOI, margin only 60bp below prior year ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Earnings%20Summary%C2%A0,restructuring%20charges%2C%20special%20items%2C%20and))), while Biopharma AOI improved 80bp on stable sales ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Adjusted%20Operating%20Income%20%28,GAAP%20Measures%22%20for)). Overall, adjusted EBIT margin (~21% in FY2024) should modestly expand as Invitae integration completes and legacy COVID-related volumes wane. We forecast FY2025 adjusted operating margin ~23%, lifting EPS by ~9–10%. In FY2024 Labcorp earned $14.57 adj EPS ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,7%20million)); for FY2025 we model mid-$16s, consistent with guidance midpoints.  

**Earnings Bridge (FY2025 vs FY2024):** Vol + OpLev – Int/Taxes = +1.0 → +1.5 (organic growth plus acquisitions) → + (stable SG&A leverage) → – (higher D&A, interest, taxes) → +$0.70 to ~$16.3.  

| Metric              | FY2022 | FY2023 | FY2024 | Q1 2025  |
|:--------------------|------:|------:|------:|--------:|
| **Revenue (B)**     |  11.9 |  12.2 |  13.0 |    3.35 |
| **Adj. EPS ($)**    |  16.7 |  13.6 |  14.6 |    3.8  |

*Source:* Labcorp financial releases ([www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorp-announces-2023-fourth-quarter-and-full-year-results#:~:text=,66)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,7%20million)).  

Labcorp’s strong cash flow (FCF ~$1.10B in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Diagnostics%20Laboratories%C2%A0,%241.25))) funds capital returns: $243M dividends, $250M repurchases in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt)). Capex/Investments have been moderate (~$840M in 2024). Net debt leverage is manageable (~0.8× equity). With ample liquidity and a historically solid balance sheet, Labcorp has room to invest in growth without compromising its financial strength.  

## Peer & Industry Analysis  
**Peers:** Labcorp competes with Quest Diagnostics (DGX), Danaher (DHR), IQVIA (IQV, ex-IMS/Quintiles) and others in the medical testing/R&D services space. Labcorp ($20B mkt cap) has delivered mid-single digit EPS growth; peers like Quest and IQVIA have similar or higher growth depending on biotech spend. Quest (market cap ~$18B) saw ~8% lab sales growth in 2024 with ERP investments (recently buying LifeLabs Canada). Danaher (mkt cap ~$280B) and IQVIA (~$60B) enjoy stronger secular growth (bioprocessing, clinical research) with ~20–30% EBITDA margins.  

| Company      | Mkt Cap | 1-Yr EPS Δ (%) | FY P/E | OP Margin | Argus Rating |
|:-------------|--------:|--------------:|-------:|----------:|-------------:|
| Labcorp (LH) | $20 B   | +8% (est.)   | ~15.5× | ~21%     | BUY         |
| Quest (DGX)  | $18 B   | ~+5%         | ~20×   | ~23%     | HOLD        |
| Danaher (DHR)| $280 B  | ~+8%         | ~25×   | ~25%     | BUY         |
| IQVIA (IQV)  | $60 B   | ~+15%        | ~22×   | ~20%     | HOLD        |

*LH = Labcorp Holdings; Data as of mid-2025.*  

On a Value/Growth map, Labcorp sits nearer the value end: it trades at a discount to high-growth peers (lower P/E) but offers stable cash returns. Its EPS growth is solid but not explosive, and the yield is modest. Industry growth is driven by demographics and rising healthcare utilization, but diagnostic volume growth is more predictable (post-COVID normalization) than biotech R&D demand. We rate Labcorp in line with broad healthcare peers: growth is steady, and valuation is attractive relative to long-term averages.  

## Financial Strength & Dividend  
**Balance Sheet:** Labcorp’s balance sheet is solid. End-2024 cash was $1.52B vs total debt $6.33B ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt)), with net leverage ~0.8× equity ($8.05B equity ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Total%20shareholders%27%20equity%20%20,%24%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%2016%2C725.1))). Working capital is positive (y/y receivables and inventory ≈$3.96B vs current liabilities ≈$2.55B ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Cash%20and%20cash%20equivalents%20,474.6))), reflecting good liquidity. The company generates ~9% of sales in FCF and maintains a conservative credit profile. We assign a **Financial Strength** rating of **Medium-High**, reflecting moderate leverage and strong cash generation.  

**Dividend and Buybacks:** Labcorp targets a progressive payout policy. The current quarterly dividend is $0.72/share (declared Apr ’25) ([www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorp-declares-quarterly-dividend#:~:text=Inc,business%20on%20May%2029%2C%202025)), annualized at $2.88 (≈1.2% yield). Dividends have risen slowly over time (from $0.67 in 2021 to $0.72 now) with a payout ratio ≈18% (operating EPS). Management also runs opportunistic buybacks (used ~$250M in 2024 ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt))). We expect share count to modestly decline over 2025 given continued repurchases. 

## Management & Risks  
Labcorp’s management is viewed as stable and transparent. **CEO Adam Schechter** (appointed 2019) has been in place through Covance integration and the Fortrea spinoff; he was named Board Chair in 2020. **CFO** (Jean-Luc Verdier, appointed 2023) leads financial strategy. The team regularly provides guideposts on volumes and margins, and detailed GAAP/non-GAAP reconciliations, aiding visibility. Correlated business segments (labs and clinical trials) mean guidance is relatively straightforward.  

**Key Risks:**  
- *Reimbursement Pressure:* Government/insurer cuts to test fees could dent revenue (e.g. proposed Medicare lab rate changes). Labcorp files claims in advance and collects later, so sticky payor policies can impact cash flows.  
- *Acquisition Integration:* Acquired businesses (e.g. Invitae assets) carry risk of execution delays or integration costs. Q2 2024 saw profit guidance cut due to Invitae expenses ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-q2-profit-revenue-estimates-demand-health-tests-2024-08-01/#:~:text=up%20from%20the%20previous%204.8,diagnostics%20unit%2C%20Labcorp%27s%20largest%20revenue)).  
- *Biopharma Demand:* Slower biotech funding (higher borrowing costs) and potential R&D cutbacks could reduce demand for its clinical lab services – growth in Q1 Biopharma was only +1.5% ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Total%20Revenue%20%20,4%29%7D)).  
- *Operational Disruptions:* Extreme weather or other events can curtail lab operations. (Q3 2024 volume was affected by Florida hurricanes ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-estimates-diagnostic-test-demand-2024-10-24/#:~:text=Labcorp%20outperformed%20Wall%20Street%20predictions,28%20billion%2C%20exceeding%20forecasts%20of)).)  
- *Competition:* Quest Diagnostics and hospital lab networks vie for market share, especially on pricing and volume incentives. Competitive pressure may cap long-run margins.  

## Company Description  
Labcorp (NYSE: LH) is a leading global life sciences services company specializing in clinical diagnostics and laboratory testing ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)). It operates an extensive network of patient service centers, clinical labs, and research facilities in ~100 countries. Its Diagnostics segment performs routine and specialty tests (blood work, pathology, genetics, etc.), serving doctors, hospitals and patients. The Drug Development (formerly Covance) segment provides lab testing and trial support for pharmaceutical and biotech clients. Labcorp employs ~70,000 people worldwide, processing over 700 million tests annually ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)). Its services span general health screening to advanced genomic and precision-medicine testing.  

## Valuation  
Our $260 target price is based on a multiple-of-earnings approach. We apply ~16× our FY2026 EPS forecast (~$16.20) to derive the target (roughly in line with peer DHR/Quest average). This represents a modest premium to Labcorp’s current ~15× FY2026E (on its mid-guidance of ~$16 EPS ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=%2A%20Full,2))) but remains below higher-growth peers. Historically, Labcorp has traded in the mid-teens P/E range; our target multiple is slightly above that, reflecting anticipated margin recovery and growth catalysts. For context, Quest trades near low-20× and Danaher in the mid-20×, while Labcorp’s current P/E (~15×) is below both. Upside is skewed to the upside given conservative estimates and potential multiple re-rating if growth outpaces current forecasts. Our rating would be downgraded to HOLD if volume growth materially slows (e.g. due to macro healthcare cuts) or if new test initiatives fail to scale as expected. Conversely, better-than-expected R&D spending or accelerated cost synergies could justify higher valuation.  

## Ratings Reference  
- **BUY:** Expect outperform – stock should exceed broad market (S&P 500) return on a risk-adjusted 12-month view.  
- **HOLD:** Expect in-line performance; returns ~market.  
- **SELL:** Expect underperform – stock likely trails broad market 12-month.  

_Long-term (5-year) bias:_ Labcorp is rated **EW (equal-weight)** versus the broad healthcare sector given balanced growth/prospects.  

## Methodology & Disclaimers  
Our analysis combines industry outlook with company-specific fundamentals. We adopt a top-down view on macro healthcare trends and regulatory environment, and a bottom-up assessment of Labcorp’s growth drivers, profitability, financial strength, and management execution. Forward projections incorporate consensus estimates, adjusted for our sector insights (aging demographics, testing trends, biotech R&D cycles) and Labcorp’s strategic initiatives (new products, M&A). Valuation models (P/E multiples, discounted cash flows) are cross-checked against comparable companies to ensure reasonableness. 

**Disclaimer:** This report is for informational purposes only and does not constitute investment advice. Argus Research Company’s ratings and forecasts are based on publicly available data and our judgment as of the report date. Market conditions and company circumstances can change, affecting returns. We undertake no obligation to update the analysis.  

## Sources  
1. Reuters – “Labcorp beats quarterly profit estimate on diagnostic test demand”, 2025-04-29 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-profit-estimate-diagnostic-test-demand-2025-04-29/#:~:text=Labcorp%20surpassed%20analysts%27%20profit%20expectations,84)).  
2. Labcorp Holdings Inc. – Q4’24 & Full-Year 2024 Results (PR Newswire, Feb 6, 2025) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,7%20million)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,%241.25)).  
3. Labcorp Holdings Inc. – Q1’25 Results (PR Newswire, Apr 29, 2025) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=,25%20billion)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Earnings%20Summary%C2%A0,restructuring%20charges%2C%20special%20items%2C%20and)).  
4. Labcorp Holdings Inc. – Quarterly Dividend Press Release, April 10, 2025 ([www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorp-declares-quarterly-dividend#:~:text=Inc,business%20on%20May%2029%2C%202025)).  
5. Reuters – “Labcorp forecasts 2025 revenue above estimates on diagnostic test demand”, 2025-02-06 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-forecasts-2025-revenue-above-estimates-diagnostic-test-demand-2025-02-06/#:~:text=Labcorp%20has%20revised%20its%202025,per%20share%2C%20with%20a%20midpoint)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Diagnostics%20Laboratories%C2%A0,%241.25)).  
6. Reuters – “Labcorp beats Q2 profit and revenue estimates on demand for health tests”, 2024-08-01 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-q2-profit-revenue-estimates-demand-health-tests-2024-08-01/#:~:text=up%20from%20the%20previous%204.8,diagnostics%20unit%2C%20Labcorp%27s%20largest%20revenue)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-q2-profit-revenue-estimates-demand-health-tests-2024-08-01/#:~:text=generator%2C%20saw%20a%207.9,forecast%20was%20adjusted%20to%20an)).  
7. Reuters – “Labcorp's quarterly results beat on diagnostic tests demand”, 2024-10-24 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/labcorp-beats-quarterly-estimates-diagnostic-test-demand-2024-10-24/#:~:text=Labcorp%20outperformed%20Wall%20Street%20predictions,28%20billion%2C%20exceeding%20forecasts%20of)).  
8. PR Newswire – “Labcorp to buy bankrupt genetic test maker Invitae for $239M”, 2024-04-25 ([www.reuters.com](https://www.reuters.com/markets/deals/clinical-lab-operator-labcorp-buy-bankrupt-genetic-test-maker-invitae-239-mln-2024-04-25/#:~:text=Labcorp%2C%20a%20laboratory%20service%20provider%2C,basis%2C%20ensuring%20continuity%20of%20operations)).  
9. Labcorp Holdings Inc. – Q4’24 Supplemental Tables ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=,funding%20of%20maturing%20debt)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=Total%20shareholders%27%20equity%20%20,%24%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%2016%2C725.1)) (cash/debt, equity).  
10. Labcorp Holdings Inc. – Q1’25 Supplemental Tables ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Earnings%20Summary%C2%A0,restructuring%20charges%2C%20special%20items%2C%20and)) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2025-first-quarter-results#:~:text=Total%20Revenue%20%20,4%29%7D)).  
11. Labcorp Holdings Inc. – About Labcorp (Company Website) ([ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-fourth-quarter-and-full-year-results#:~:text=About%20Labcorp%20Labcorp%20,tests%20annually%20for%20patients%20around)).